Addressing Multiplicity Issues of a Composite Endpoint and Its Components in Clinical Trials

ISSN： 1054-3406

Source： Journal of Biopharmaceutical Statistics, Vol.21, Iss.4, 2011-07, pp. : 610-634

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Composite Endpoints for Clinical Trials: Current Perspectives

By Kleist Peter

International Journal of Pharmaceutical Medicine, Vol. 21, Iss. 3, 2007-01 ,pp. : 187-198

Adis International

Access to resources Recommend Favorite

Ethical Issues in Phase I Cancer Clinical Trials

By Peppercorn Jeffrey

International Journal of Pharmaceutical Medicine, Vol. 20, Iss. 4, 2006-01 ,pp. : 233-242

Adis International

Access to resources Recommend Favorite

Clinical Trials in Children: Ethical and Practical Issues

By Golombek Sergio G.

International Journal of Pharmaceutical Medicine, Vol. 21, Iss. 2, 2007-01 ,pp. : 121-129

Adis International

Access to resources Recommend Favorite

Randomized Clinical Trials in Children - Ethical and Methodological Issues

Current Pharmaceutical Design, Vol. 16, Iss. 22, 2010-07 ,pp. : 2407-2415

Bentham Science Publishers

Access to resources Recommend Favorite

Use of the Sustained Pain-Free Plus No Adverse Events Endpoint in Clinical Trials of Triptans in Acute Migraine

By Dodick David W.

CNS Drugs, Vol. 21, Iss. 1, 2007-01 ,pp. : 73-82

Adis International

Access to resources Recommend Favorite